Clinical Trial Update: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma [Phase 1, Phase 2]

View source ↗

Summary

Regeneron’s cemiplimab (REGN2810) was studied in pediatric patients with relapsed/refractory solid tumors and CNS tumors, including a safety/efficacy assessment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors
• Diffuse Intrinsic Pontine Glioma
• Glioma
• High-grade Glioma
• Solid Tumors

Drugs mentioned

• Cemiplimab (REGN2810) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-10-09